NASDAQ:SHPG Shire (SHPG) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free SHPG Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$179.20▼$179.2050-Day Range$179.20▼$179.2052-Week Range$123.73▼$182.47VolumeN/AAverage Volume2.21 million shsMarket Capitalization$54.71 billionP/E Ratio11.83Dividend Yield0.19%Price TargetN/A Stock AnalysisStock Analysis Get Shire alerts: Email Address Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About Shire Stock (NASDAQ:SHPG)Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.Read More Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. SHPG Stock News HeadlinesOctober 15, 2023 | investing.comSHPG Historical DataMarch 30, 2023 | thestreet.comShire Stock Hits New 52-Week High (SHPG)May 5, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...October 19, 2022 | bbc.comEthiopia's Tigray conflict: Nasa shows how a war zone faded from space - BBCOctober 18, 2022 | bbc.comEthiopia civil war: Hyenas scavenge on corpses as Tigray forces retreat - BBCOctober 18, 2022 | news.yahoo.comEthiopia civil war: Federal army seizes strategic city of Shire - Yahoo NewsOctober 17, 2022 | washingtonpost.comEthiopian war in Tigray intensifies as government soldiers capture strategic Shire - The Washington PostSeptember 25, 2022 | dailymail.co.ukMum saves toddler with CPR in Sydney's Hills Shire: Triple-0 call revealed: Police Defibrillators - Daily MailMay 5, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...September 15, 2022 | cbsnews.com"Hobbit home" up for sale in River Falls, Wisconsin - CBS NewsSeptember 10, 2022 | npr.orgFresh Air Weekend: Tennis great John McEnroe; Musician Amanda Shires - NPRSeptember 10, 2022 | npr.orgBest Of: John McEnroe / Amanda Shires : Fresh Air - NPRSeptember 7, 2022 | npr.orgAmanda Shires : Fresh Air - NPRSeptember 5, 2022 | theguardian.comMLB’s Art Shires: hitter, peacock, boaster, boxer and accused killer - The GuardianSeptember 1, 2022 | countrystandardtime.comAmanda Shires - Take It Like A Man - Country Standard TimeAugust 10, 2022 | theguardian.comDreaming shires: how East Yorkshire shaped Tolkien’s Middle-earth fantasy - The GuardianAugust 3, 2022 | npr.orgOn 'Take It Like a Man,' Amanda Shires takes aim for the heavens - NPRJuly 29, 2022 | theguardian.comAmanda Shires: Take It Like a Man review – reimagining country strong - The GuardianJuly 21, 2022 | nytimes.comAmanda Shires Isn’t Letting Nashville, or Her Marriage, Off the Hook - The New York TimesJuly 18, 2022 | dailymail.co.ukCat ban in Australia: Bass Coast Shire near Melbourne to fine pet owners if feline is outdoors - Daily MailJuly 17, 2022 | dailymail.co.ukNathan Brown lists $1.62million waterfront home in Sydney for sale - Daily MailJune 23, 2022 | yahoo.comCountry singer Amanda Shires explains why she told her abortion story: 'It's part of my character to speak up' - Yahoo LifeJune 17, 2022 | dallasnews.comRichardson retail and office center is latest commercial property sale - The Dallas Morning NewsMay 26, 2022 | dailymail.co.uk'Flood refugee' races to spruce up Scott Morrison's Shire home as he leaves Kirriblli House - Daily MailMay 10, 2022 | bizjournals.comIgnite Entertainment opens Shires' Cafe downtown at City Club Apartments - Cincinnati Business Courier - The Business JournalsApril 26, 2022 | law360.com2nd Circ. Affirms Shire Sanctions In Pharma IP Fight - Law360April 11, 2022 | afr.comSydney property: “There's money in the shire, it's crazy”, says agent who just sold a Cronulla home with no water views for $4.9 million - The Australian Financial ReviewSee More Headlines Receive SHPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shire and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/26/2018Today5/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SHPG CUSIPN/A CIK936402 Webwww.shire.com Phone353-1609-6000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)$15.15 Trailing P/E Ratio11.83 Forward P/E Ratio11.88 P/E Growth1.54Net Income$4.27 billion Net Margins30.63% Pretax MarginN/A Return on Equity12.70% Return on Assets7.06% Debt Debt-to-Equity Ratio0.36 Current Ratio0.92 Quick Ratio0.51 Sales & Book Value Annual Sales$15.16 billion Price / Sales3.61 Cash Flow$22.71 per share Price / Cash Flow7.89 Book Value$119.43 per share Price / Book1.50Miscellaneous Outstanding Shares305,280,000Free FloatN/AMarket Cap$54.71 billion OptionableOptionable Beta0.87 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Flemming Ornskov M.P.H. (Age 60)MBA, M.D., MPH, CEO, MD & Exec. Director Mr. Thomas J. W. Dittrich (Age 54)CFO & Director Gisele DionChief Accounting OfficerMr. Matthew Walker (Age 54)Head of Technical Operations Dr. Andreas Busch Ph.D. (Age 55)Head of R&D and Chief Scientific Officer Key CompetitorsTakeda PharmaceuticalNYSE:TAKZoetisNYSE:ZTSGSKNYSE:GSKBristol-Myers SquibbNYSE:BMYGenmab A/SNASDAQ:GMABView All Competitors Should I Buy Shire Stock? SHPG Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Shire plc: Shire plc has shown consistent growth in its stock price over the past year, indicating a positive trend. The company has a strong institutional ownership percentage, which can provide stability and confidence to investors. Recent developments in Shire plc's product pipeline show promising potential for future revenue growth. Shire plc's average daily volume indicates active trading, providing liquidity for investors. With a low short percentage of float, there is less speculative pressure on the stock price. Cons Investors should be bearish about investing in Shire plc for these reasons: Shire plc's outstanding shares are currently at 0, which may raise concerns about the company's financial structure. The company's float size is 0, potentially limiting the stock's liquidity and trading opportunities. Shire plc's recent month-to-month change in shorted shares percentage indicates increased bearish sentiment among investors. Days to cover ratio of 0.4 suggests a higher risk of short squeezes due to a relatively low number of days required to cover short positions. The company's fifty-two week performance has been relatively flat, signaling potential stagnation in stock price movement. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Shire pros and cons to contact@marketbeat.com. SHPG Stock Analysis - Frequently Asked Questions How were Shire's earnings last quarter? Shire plc (NASDAQ:SHPG) released its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.58 by $0.28. The biopharmaceutical company had revenue of $3.77 billion for the quarter. Shire had a net margin of 30.63% and a trailing twelve-month return on equity of 12.70%. Shire's revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the prior year, the business posted $3.63 EPS. Is Shire a good dividend stock? Shire (NASDAQ:SHPG) pays an annual dividend of $0.34 per share and currently has a dividend yield of 0.19%. The dividend payout ratio is 2.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SHPG will have a dividend payout ratio of 2.15% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for SHPG. What other stocks do shareholders of Shire own? Based on aggregate information from My MarketBeat watchlists, some companies that other Shire investors own include Gilead Sciences (GILD), Intel (INTC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), Walt Disney (DIS), Johnson & Johnson (JNJ), Pfizer (PFE), Starbucks (SBUX) and Exxon Mobil (XOM). This page (NASDAQ:SHPG) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shire plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.